IP Library Granted Patent US 8,846,603
Granted Patent B2
US 8,846,603 · App. 13/583,973 · Granted Sep 30, 2014

NPP1 fusion proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,603
App. No.
13/583,973
Granted
Sep 30, 2014
Kind
B2
Abstract

The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.

Claims (19)

1. An isolated NPP1 fusion protein, comprising an NPP1 component, a targeting moiety, and an Fc region of an immunoglobulin, wherein a) the NPP1 component comprises the cysteine-rich region and the C-terminus catalytic domain of NPP1, b) the targeting moiety and the Fc region are each located C-terminally to the NPP1 component, and c) the isolated NPP1 fusion protein has NPP1 enzymatic activity.

2. The NPP1 fusion protein of claim 1 , wherein said NPP1 enzymatic activity is pyrophosphatase activity, phosphodiesterase activity or pyrophosphatase and phosphodiesterase activity.

3. The NPP1 fusion protein of claim 1 , wherein said polypeptide is a recombinant protein.

4. The NPP1 fusion protein of claim 1 , wherein said targeting moiety is chemically linked to said catalytic domain of NPP1.

5. The NPP1 fusion protein of claim 1 , wherein said NPP1 component consists of P99 through D925 of SEQ ID NO: 1.

6. The NPP1 fusion protein of claim 5 , wherein said targeting moiety is a peptide comprising at least four negatively charged amino acid residues.

7. The NPP1 fusion protein of claim 5 , wherein said targeting moiety is a peptide comprising between about five and about fifteen negatively charged amino acid residues.

8. The polypeptide NPP1 fusion protein of claim 7 , wherein said negatively charged amino acid residues comprise about eight consecutive aspartic acid or glutamic acid residues.

9. The NPP1 fusion protein of claim 7 , wherein said negatively charged amino acid residues comprise at least four aspartic acid residues.

10. The NPP1 fusion protein of claim 7 , wherein said negatively charged amino acid residues comprise at least four glutamic acid residues.

11. The NPP1 fusion protein of claim 7 , wherein said negatively charged amino acid residues comprise eight consecutive aspartic acid residues.

12. The NPP1 fusion protein of claim 5 , wherein said targeting moiety is fused to the C-terminus of said catalytic domain of NPP1.

13. The NPP1 fusion protein of claim 5 , wherein said Fc region is fused to the C-terminus of said catalytic domain of NPP1.

14. The NPP1 fusion protein of claim 1 , wherein said fusion protein further comprises a polypeptide linker between said targeting moiety and said catalytic domain of NPP1.

15. The NPP1 fusion protein of claim 1 , wherein said fusion protein further comprises a signal peptide.

16. The NPP1 fusion protein of claim 1 herein said fusion protein forms a homodimer.

17. The NPP1 fusion protein of claim 1 , wherein said fusion protein protein is a monomer.

18. An isolated nucleic acid encoding the NPP1 fusion protein of claim 1 .

19. A replication or expression vector carrying the isolated nucleic acid of claim 18 .

Assignments (7)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2025
From: INOZYME PHARMA, INC.
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 073707/0488 →
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE OF THE ASSIGNMENT PREVIOUSLY RECORDED AT REEL: 040361 FRAME: 0470. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 9, 2021
From: ALEXION PHARMA LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 057127/0791 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2020
From: ALEXION PHARMACEUTICALS, INC.
To: INOZYME PHARMA, INC.
Reel/Frame 054449/0251 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: ALEXION PHARMA LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 040361/0470 →
MERGER AND CHANGE OF NAME Recorded Nov 15, 2016
From: SYNAGEVA BIOPHARMA CORP.; GALAXY MERGER SUB LLC
To: ALEXION PHARMA LLC
Reel/Frame 040329/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2013
From: QUINN, ANTHONY; HARVEY, ALEX J.; XIA, ZHINAN
To: SYNAGEVA BIOPHARMA CORP.
Reel/Frame 030267/0730 →